OBIO

Orchestra BioMed Holdings, Inc. (OBIO) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Orchestra BioMed is a biomedical innovation company focused on developing high-impact technologies through risk-reward sharing partnerships. Its flagship candidates are AVIM Therapy (for hypertension) and Virtue SAB (for atherosclerotic artery disease). The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Note: Debt obligations include the Royalty Purchase Agreement ($17.79M) and Loan Payable ($14.33M). The $20.0M Medtronic Loan was received in May 2026, subsequent to the balance sheet date.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 87% to $0.11 million. This was driven by the termination of the Terumo Agreement in October 2025, which eliminated $0.73 million in partnership revenue recognized in Q1 2025. Product revenue from FreeHold Surgical decreased 19% to $0.11 million due to lower sales volume.
• Increased Operating Expenses: Research and Development (R&D) expenses increased 17% to $15.78 million, primarily due to increased headcount and clinical development costs for the BACKBEAT and Virtue trials. Selling, General, and Administrative (SG&A) expenses remained relatively flat, increasing 2% to $6.37 million.
• Non-Operating Gains: The company recognized a $2.24 million gain on the sale of strategic investments (Vivasure Medical Limited) following its acquisition by Haemonetics Corporation. This partially offset the operating loss.
• Interest Expense: Net interest expense increased significantly to $0.82 million (from income of $0.17 million in Q1 2025) due to interest on the Royalty Purchase Agreement and the 2024 Loan and Security Agreement.

Guidance, Outlook, and Risks

• Clinical Milestones: The company targets completion of enrollment for the BACKBEAT Trial (AVIM Therapy) by the end of Q3 2026. The Virtue Trial (Virtue SAB) enrollment is planned for completion in 2027.
• Regulatory Progress: In April 2026, the FDA granted a second Breakthrough Device Designation (BDD) for AVIM Therapy, expanding the addressable U.S. patient population to over 7.7 million.
• Liquidity Outlook: Management believes current cash, marketable securities, and proceeds received subsequent to March 31, 2026 (including $20M from Medtronic and $15M from Ligand), are sufficient to fund operations into the fourth quarter of 2027.
• Financing Activities: The company raised approximately $5.9 million net proceeds via an At-The-Market (ATM) offering in Q1 2026. Approximately $92.4 million remains available under the ATM facility.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital, and reliance on third-party partners (Medtronic) for commercialization. The company has an accumulated deficit of $383.3 million and expects to incur substantial losses in the future.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $94.4 million liquidity position against the projected burn rate to confirm the Q4 2027 funding horizon.
• Debt Covenants: Review the terms of the Royalty Purchase Agreement (effective interest rate ~23.3%) and the 2024 Loan and Security Agreement for potential covenant triggers or prepayment penalties.
• Clinical Enrollment: Monitor the progress of the BACKBEAT Trial enrollment against the Q3 2026 target, as delays could impact future financing needs.
• Revenue Recognition: Confirm the timeline for potential revenue recognition under the Amended Medtronic Agreement, as no revenue has been recognized to date.
• Strategic Investment Proceeds: Track the receipt of the remaining milestone payments (up to $6.0 million) from the Vivasure acquisition.